<DOC>
	<DOCNO>NCT02380248</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Systane® Gel Drops dry eye subject follow 90 day QID ( 4 times/day ) dosing . This study conduct India .</brief_summary>
	<brief_title>Clinical Evaluation Systane® Gel Drops Dry Eye Subjects</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Must give informed consent , willing able attend study visit . Bestcorrected visual acuity ( BCVA ) ≥ 55 letter eye measure ETDRS ( letter read method ) . Dry eye eye diagnose ophthalmologist . Other protocolspecified inclusion criterion may apply . Women childbearing potential pregnant , test positive pregnancy test , breastfeed . Any medical condition ( systemic ophthalmic ) may , opinion Investigator , preclude safe administration test article safe participation study . Any contraindication hypersensitivity study medication component . Ocular surgery ( type , include PRK , LASIK , Epilasik , etc . ) ocular trauma require medical pharmacological treatment within 1 year Screening . Use topical ocular prescription nonprescription medication , RESTASIS topical ocular steroid within 14 day Screening . Chronic medication ( counter , prescription , vitamin ) stable dose least 30 day prior Screening . Contact lens wear within 1 week Screening and/or unwillingness discontinue contact lens wear duration study . Participation clinical trial within 30 day prior Screening . Other protocolspecified exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>